Clinical trials have demonstrated tofersen’s ability to significantly reduce neurofilament light chain (NfL) levels in plasma, indicating potential disease-modifying effects, although improvements in ALS functional rating scale revised (ALSFRS-R) have varied [11]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.